Sylvia A. Sarnik

Sylvia A. Sarnik

Auto-generated profile, based on publicly available information

Sylvia A. Sarnik

University of California Berkeley

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 July 2022 in Nature Genetics
Verified
Journal Article
Open access
PDF file
Scott B. BieringScott B. Biering
Scott B. Biering
SSSylvia A. Sarnik
Sylvia A. Sarnik
EWEleanor Wang
Eleanor Wang
JZJames R. Zengel
James R. Zengel
SLSarah R. Leist
Sarah R. Leist
PHPatrick D. Hsu
Patrick D. Hsu
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) causes a range of symptoms in infected individuals, from mild respiratory illness to acute respiratory distress syndrome. A systematic understanding of host factors influencing viral infection is critical to elucidate SARS-CoV-2–host interactions and the progression of Coronavirus disease 2019 (COVID-19). Here, we conducted genome-wide CRISPR knockout and activation screens in human lung epithelial cells with endogenous expression of the SARS-CoV-2 entry factors ACE2 and TMPRSS2. We uncovered proviral and antiviral factors across highly interconnected host pathways, including clathrin transport, inflammatory signaling, cell-cycle regulation, and transcriptional and epigenetic regulation. We further identified mucins, a family of high molecular weight glycoproteins, as a prominent viral restriction network that inhibits SARS-CoV-2 infection in vitro and in murine models. These mucins also inhibit infection of diverse respiratory viruses. This functional landscape of SARS-CoV-2 host factors provides a physiologically relevant starting point for new host-directed therapeutics and highlights airway mucins as a host defense mechanism.

23 April 2021 in bioRxiv
Verified
Preprint
Open access
PDF file
Scott B. BieringScott B. Biering
Scott B. Biering
SSSylvia A. Sarnik
Sylvia A. Sarnik
EWEleanor Wang
Eleanor Wang
JZJames R. Zengel
James R. Zengel
VSVarun Sathyan
Varun Sathyan
PHPatrick D. Hsu
Patrick D. Hsu
SUMMARY: SARS-CoV-2 can cause a range of symptoms in infected individuals, from mild respiratory illness to acute respiratory distress syndrome. A systematic understanding of the host factors mediating viral infection or restriction is critical to elucidate SARS-CoV-2 host-pathogen interactions and the progression of COVID-19. To this end, we conducted genome-wide CRISPR knockout and activation screens in human lung epithelial cells with endogenous expression of the SARS-CoV-2 entry factors ACE2 and TMPRSS2. These screens uncovered proviral and antiviral host factors across highly interconnected host pathways, including components implicated in clathrin transport, inflammatory signaling, cell cycle regulation, and transcriptional and epigenetic regulation. We further identified mucins, a family of high-molecular weight glycoproteins, as a prominent viral restriction network. We demonstrate that multiple membrane-anchored mucins are critical inhibitors of SARS-CoV-2 entry and are upregulated in response to viral infection. This functional landscape of SARS-CoV-2 host factors provides a physiologically relevant starting point for new host-directed therapeutics and suggests interactions between SARS-CoV-2 and airway mucins of COVID-19 patients as a host defense mechanism.

18 August 2020 in Cytometry Part A
Verified
Journal Article
Closed access
PDF file
SSSylvia A. Sarnik
Sylvia A. Sarnik
BSBryan A. Sutermaster
Bryan A. Sutermaster
EDEric M. Darling
Eric M. Darling

14 September 2022 in bioRxiv
Verified
Preprint
Open access
PDF file
MSMadison Strine
Madison Strine
WCWesley Lam Cai
Wesley Lam Cai
JWJin Wei
Jin Wei
MAMia Madel Alfajaro
Mia Madel Alfajaro
RFRenata B. Filler
Renata B. Filler
CWCraig Wilen
Craig Wilen
Identifying host genes essential for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has the potential to reveal novel drug targets and further our understanding of coronavirus disease 2019 (COVID-19). We previously performed a genome-wide CRISPR/Cas9 screen to identify pro-viral host factors for highly pathogenic human coronaviruses. Very few host factors were required by diverse coronaviruses across multiple cell types, but DYRK1A was one such exception. Although its role in coronavirus infection was completely unknown, DYRK1A encodes D ual Specificity T y rosine Phosphorylation R egulated K inase 1A and regulates cell proliferation, and neuronal development, among other cellular processes. Interestingly, individuals with Down syndrome overexpress DYRK1A 1.5-fold and exhibit 5-10x higher hospitalization and mortality rates from COVID-19 infection. Here, we demonstrate that DYRK1A regulates ACE2 and DPP4 transcription independent of its catalytic kinase function to support SARS-CoV, SARS-CoV-2, and MERS-CoV entry. We show that DYRK1A promotes DNA accessibility at the ACE2 promoter and a putative distal enhancer, facilitating transcription and gene expression. Finally, we validate that the pro-viral activity of DYRK1A is conserved across species using cells of monkey and human origin and an in vivo mouse model. In summary, we report that DYRK1A is a novel regulator of ACE2 and DPP4 expression that may dictate susceptibility to multiple highly pathogenic human coronaviruses. Whether DYRK1A overexpression contributes to heightened COVID-19 severity in individuals with Down syndrome through ACE2 regulation warrants further future investigation.